Dexrazoxane monoHCl (formerly also known as ICRF-187, ADR-529) acts as an intracellular iron chelator, which decreases the formation of superoxide radicals, and is mainly used as a cardioprotective agent. As a derivative of EDTA, dexrazoxane chelates iron, but the precise mechanism by which it protects the heart is not known. This agent is used to protect the heart against the cardiotoxic side effects. Dexrazoxane (10 mM), known clinically to limit anthracycline cardiac toxicity, prevents daunorubicin-induced myocyte apoptosis, but not necrosis induced by higher anthracycline concentrations in rat cardiac myocytes.

纯度：≥98%

CAS：1263283-43-7